Phosphatidylserine (PS), normally restricted to the inner leaflet of the plasma membrane, becomes exposed on the outer surface of viable endothelial cells in tumor vasculature, but not in normal blood vessels. In the present study, we report the use of PGN635, a novel human monoclonal antibody that specifically targets PS, for in vivo molecular MRI of tumor vasculature. The F(ab ) 2 fragments of PGN635 were conjugated to polyethylene glycol (PEG) coated iron oxide nanoparticles (IO). Targeting specificity of the PS-targeted nanoprobes, IO-PGN635F(ab ) 2 was first confirmed by in vitro MRI and histological staining. In vivo longitudinal MRI was then performed before and after i.v. injection of IO-PGN635F(ab ) 2 into mice bearing breast 4T1 tumors. T 2 -weighted MR images at 9.4 T revealed inhomogeneous signal loss in tumor as early as 2 h post injection. Furthermore, ionizing radiation induced a significant increase in PS exposure on tumor vascular endothelial cells, resulting in significantly enhanced and sustained tumor contrast (p < 0 05). Spatially heterogeneous MRI contrast correlated well with histological staining of tumor vascular endothelium. Our studies suggest that PS exposed within the lumen of tumor vasculature is a highly specific and useful biomarker for targeted MRI contrast agents.
INTRODUCTION
Molecular imaging of angiogenesis has recently been demonstrated using ligands that target biomarkers that are selectively expressed on tumor vasculature. [1] [2] [3] [4] The integrin v 3 , which is over expressed on the surface of tumor vascular endothelial cells, has been the most widely used target for imaging tumor angiogenesis. Various imaging contrast agents have been conjugated to v 3 binding ligands, such as Arginine-Glycine-Aspartic Acid (RGD)-containing peptide, for optical imaging, PET, SPECT and MRI. 3 5-8 In addition to its over expression in angiogenic endothelial cells (EC), v 3 and several other integrins found to present abundantly on tumor cells play an important role on mediating interactions between tumor cells and their extracellular environment. A recent study by Schnell, et al. has exploited [ 18 F] Galacto-RGD for PET imaging of v 3 expression in GBM patients. 9 Phosphatidylserine (PS) is the most abundant anionic phospholipid of the cell membrane and is normally found on the inside of the cell. It is now known that PS becomes exposed on the outer surface of viable endothelial cells in tumor blood vessels. 10 11 Studies have shown that characteristics of tumor environment, in particular, hypoxia, acidity, inflammatory cytokines and the elevated oxidative stress contribute to PS exposure on ECs. 10 12 Vascular endothelium in normal tissues, even in those highly angiogenic ovarian blood vessels during ovulation, lacks exposed PS. 13 Along with its localization on vascular lumen, PS represents an ideal biomarker for vascular targeted imaging. Thorpe's lab has developed a series of monoclonal antibodies that recognize PS with higher specificity than does annexin V. 10 14 15 Several of these antibodies bind to PS complexed with the PSbinding protein, 2-glycoprotein I ( 2GP1). 15 16 Bavituximab, a chimeric monoclonal PS-targeting antibody, is in advanced clinical trials in patients with lung and breast cancer. 17 A new, fully human monoclonal PS targeting antibody, PGN635 has recently been developed. 18 Like bavituximab, PGN635 has a high specificity and affinity to PS (K d ≈ 10 −10 M). We have previously conjugated the F(ab ) 2 fragments of PGN635 to an NIR dye, IRDye800CW. The 800CW-PGN635F(ab ) 2 enabled sensitive and clear optical imaging of glioma mouse models. 18 However, due to its inherent low spatial resolution and penetration depth, optical imaging is not ideal to provide spatial information about intratumoral distribution of the probes. The goal of this study was to determine if PGN635F(ab ) 2 could be used to generate a MRI contrast agent that specifically targets tumor vasculature. MRI is a commonly used imaging modality with high spatial resolution and excellent soft tissue contrast. We conjugated amino-terminal PGN635F(ab ) 2 to carboxyl groups on the distal terminus of PEG chains that are coated on the surface of superparamagnetic iron oxide nanoparticles (SPIO). Specificity of IO-PGN635F(ab ) 2 binding to exposed PS was first studied in vitro on cultured vascular endothelial cells and tumor cells by histological staining and MRI. High field 9.4 T MRI was then applied to detect T 2 -weighted signal intensity change in subcutaneous 4T1 tumors post i.v. injection of IO-PGN635F(ab ) 2 . Radiotherapy is known to increase PS exposure on vascular endothelium. Therefore, to explore whether IO-PGN635F(ab ) 2 could be used to monitor dynamic changes in levels of exposed PS, 4T1 tumors were imaged after irradiation and differences in spatial distribution and quantity of IO-PGN635F(ab ) 2 was analyzed. Histological analysis of Prussian blue staining and immunohistochemistry were finally used to confirm that IO-PGN635F(ab ) 2 localized to the vasculature in tumor tissues.
METHODS
Preparation of PGN635F(ab ) 2 Fragments and Labeling with IO Nanoparticles The human monoclonal antibody PGN635 was generated by Affitech A.S. (Oslo, Norway) in collaboration with Peregrine Pharmaceuticals. Inc., (Tustin, CA). It was produced under serum-free conditions by Avid Bioservices (Tustin, CA). Aurexis is a human monoclonal antibody that binds to an irrelevant antigen (S. aureus clumping factor A) and was used as a negative control antibody. PGN635 and Aurexis F(ab ) 2 fragments were generated by reacting antibodies with pepsin at a molar ratio of 1:130 (antibody:pepsin) for 1 hr at 37 C. F(ab ) 2 fragments (M W = 110 kD) were purified by FPLC using an S-200 column (Pharmacia, Piscataway, NJ) and PBS running buffer. F(ab ) 2 fragments were then conjugated to polyethylene glycol (PEG) coated super paramagnetic iron oxide (SPIO) nanoparticles with the iron oxide core diameter of 20 nm (SPP-20; Ocean Nanotech, AR). Briefly, carboxyl (-COOH) group on the distant terminus of the PEG chain of SPIO (1 mg) were activated with 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) and N -hydroxysuccinimide (NHS) for 15 min, resulting in a semi-stable NHS or sulfo-NHS ester, which were reacted with amino-group-containing antibody fragments (1 mg) at room temperature for 2 hrs with continuous mixing to yield amide bond. The conjugates were separated from unbound antibody fragments overnight at 4 C by using a DynaMag ™ (Invitrogen, Grand Island, NY) magnetic separator. The products are referred to as IO-PGN635F(ab ) 2 or IO-AurexisF(ab ) 2 . The iron concentration of IO-F(ab ) 2 was determined by atomic absorption spectrometer (SpectrAA 50 spectrometer; Varian Inc., Palo Alto, CA). The core size and hydrodynamic size of the nanoparticles before and after conjugation were measured by transmission electron microscope (JEOL-1200EX, Japan) and dynamic light scattering using Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). MRI relaxivity was measured with various iron concentrations of the conjugates embedded homogeneously in 0.8% agarose. By fitting the values of 1/T 1 or 1/T 2 at different concentrations, the relaxivities r 1 and r 2 were determined.
The number of antibody fragments that were bound to each iron oxide nanoparticle was estimated by measuring the fluorescence intensity of near infrared dye labeled IO-F(ab ) 2 . F(ab ) 2 was first labeled with IRDye-800CW (Li-COR, Lincoln, NE), as described previously. 18 The 800CW-F(ab ) 2 was then conjugated with iron nanoparticles using aforementioned procedures. Optical light intensity of 800CW-F(ab ) 2 or IO-F(ab ) 2 -800CW at various concentrations was obtained at the emission wavelength of 778 nm and used to determine the number of F(ab ) 2 using a Maestro imaging system (CRI Inc. Woburn, MA). 19 In Vitro Binding Specificity of IO-PGN635F(ab ) 2 Adult bovine aortic endothelial (ABAE) cells (Clonetics, Walkersville, MD) and 4T1 mouse breast carcinoma cells (American Type Cell Collection, Rockville, MD) were maintained in Dulbecco modified Eagle medium supplemented with 10% FBS and 2 mM L-glutamine. To induce PS exposure, the cells were treated with a single dose of 6 Gy X-radiation. 24 hrs later, the irradiated or sham irradiated cells were incubated with IO-PGN635F(ab ) 2 or the control IO-AurexisF(ab ) 2 at a concentration of 36 g/ml iron for 1 hr. For the blocking study, the cells were pretreated with full length PGN635 (710 g/ml) for 1 hr prior to IO-PGN635F(ab ) 2 . Unbound particles were washed away with PBS, and then the cells were fixed with 4% paraformaldehyde (PFA). Prussian blue staining was performed to stain iron and counterstained by nuclear fast red.
In Vitro MRI of Binding Specificity of IO-PGN635F(ab ) 2 4T1 cells that were irradiated or sham irradiated 24 hrs earlier were incubated with IO-PGN635F(ab ) 2 at different concentrations (18, 36 and 61 g/ml iron) or IO-AurexisF(ab ) 2 (36 g/ml iron) for 1 hr. The same blocking study was performed here. After washing off all the unbound particles with PBS, 3 × 10 5 cells were mixed homogeneously with 0.8% agarose in 96-well-dish. The phantoms were imaged on a 9.4-T horizontal bore magnet with a Varian INOVA Unity system (Palo Alto, CA). A fast spin-echo multi-slice sequence (FSEMS; TR = 3000 ms, effective TE ranging from 40 to 120 ms with a 20 ms increment, average = 2, number of slices = 10, acquisition time = 10 min) was used to acquire T 2 -weighted images and obtain quantitative T 2 values.
Tumor Model
All animal procedures were approved by the Institutional Animal Care and Use Committee of University of Texas Southwestern Medical Center. Two million 4T1 cells in 100 l of serum-free medium containing 25% Matrigel (BD Biosciences, San Jose, CA) were injected subcutaneously on both thighs of anesthetized mice (n = 12; BALB/c nu/nu, 6-8 weeks old; NCI, Frederick, MD). Animals were sedated with 3% isoflurane and maintained under general anesthesia (2% isoflurane).
Radiation Treatment
When subcutaneous tumors on both thighs reached 6-8 mm in diameter, a single dose of 12 Gy of irradiation was delivered to the tumors on the left thigh using a small animal irradiator (XRAD320; Precision X-ray, Inc, North Branford, CT) fitted with a variable collimator to generate a single adjustable collimated iso-dose beam of X-rays at a dose rate of 10 Gy/min.
Detection and Quantification of Exposed PS In Vivo
Mice bearing two thigh tumors were given a single dose of 12 Gy irradiation to the left tumor to induce exposed PS, as described above. Twenty-four hours later, 150 g of PGN635 or the control body Aurexis were injected i.v. and allowed to circulate for 4 hrs. The mice were anesthetized, exsanguinated, and perfused with heparinized saline. The tumors on both sides and adjacent muscular tissues were removed and frozen for preparation of cryosections. Vascular endothelium was stained using a rat anti-mouse CD31 antibody (BD Biosciences, San Jose, CA) followed by Cy3-labeled goat anti-rat IgG. PGN635 or Aurexis was detected using goat anti-human IgG conjugated to Cy2. Doubly labeled endothelial cells (i.e., CD31 positive/PGN635 positive) were identified by yellow fluorescence on merged images. The percentage of doubly positive vessels was calculated as follows: (mean number of yellow vessels per field/mean number of total vessels) ×100. Ten random 0.079 mm 2 fields were evaluated for each section.
In Vivo MRI of Vascular Targeted IO-PGN635F(ab ) 2 Nanoprobes in 4T1 Tumors When the subcutaneous tumors reached ∼ 5 mm in diameter, in vivo MRI studies at 9.4 T magnet were conducted 24 hrs after radiation. Animals were sedated with 3% isoflurane and maintained under general anesthesia (1.5% isoflurane). Animal body temperature and respiration were monitored and maintained constant throughout the experiment (SA Instruments Inc., Stony Brook, NY, USA). The same FSEMS sequence as used for in vitro study was applied for in vivo image acquisition. A series of FSEMS (number of slices = 10) images was acquired before and at different time points, typically 2, 4, 8, 24 and 48 hrs after i.v. injection of IO-PGN635F(ab ) 2 (n = 6) or IOAurexisF(ab ) 2 (n = 4; 2.5 mg iron/kg body weight in 120 l volume) via a tail vein.
Analysis of MRI data was performed on a home written MATLAB program on both pixel-by-pixel and region of interest (ROI) basis. 20 ROIs were drawn on both the tumors and adjacent thigh muscles on the high resolution T 2 -weighted images. Signal intensity (SI) in these ROIs was measured for all the echoes of FSEMS images and a ratio of tumor to muscle (TMR) was obtained. To provide the spatial distribution of IO-PGN635F(ab ) 2 nanoprobes in tumors, 'hot-spot' maps showing the area with significantly low SI was created based on a pixel by pixel analysis. Hot-spots were identified as voxels with SI values (based on effective TE = 80 ms) lower than 2 standard deviation of the baseline tumor parenchyma. Hot-spots were then overlaid on the corresponding high resolution T 2 -weighted images. The total area of the hot-spots in individual MRI slices was summed and then divided by the whole tumor area to obtain the fraction of hot-spots.
Histological and Immunohistochemical Analysis
Immediately after MRI scanning, tumor-bearing mice were sacrificed and tumor tissues were harvested. The cryosections were immunostained with antibodies to the endothelial marker, CD31 (BD Biosciences) followed by horseradish peroxidase (HRP)-conjugated goat anti rat secondary antibody (Serotec, Raleigh, NC). The same sections were then used for Prussian blue staining to detect IO-PGN635F(ab ) 2 nanoprobes and observed under microscope to localize IO-PGN635F(ab ) 2 and their overlapping with tumor vascular endothelial cells.
Statistical Analysis
Statistical significance was assessed using an analysis of variance (ANOVA) on the basis of Fisher's protected least significant difference (PLSD; Statview; SAS Institute Inc., Cary, NC) or Student's t tests.
RESULTS

Characterization of IO-PGN635F(ab ) 2 Nanoprobes
The average hydrodynamic size of IO nanoparticles before conjugation was 23.3 nm compared to 24.1 nm on the manufacturer's manual (Fig. 1) . After conjugation the average hydrodynamic size of IO-PGN635F(ab ) 2 became 24.7 nm (Fig. 1) . IO-PGN635F(ab ) 2 had a Zeta potential as −5 8 mV. MRI relaxivity of IO-PGN635F(ab ) 2 at 9.4T was obtained: r 1 = 0 064 mM −1 s −1 and r 2 = 255 3 mM −1 s −1 , indicating it as a strong T 2 contrast agent. Based on the measurement of fluorescence intensity produced from NIR-800CW dye conjugated to IO-PGN635F(ab ) 2 , we estimate that approximately 18 antibody fragments are attached to each nanoparticle via a covalent bond between the amino group of the antibody and the distal terminus of the polyethylene glycol (PEG) coated on the nanoparticle. No precipitation was visible in the solution of the conjugates for at least 2 weeks.
PS-Targeting Specificity of IO-PGN635F(ab ) 2 Nanoprobes In Vitro Under the normal culture condition, there was essentially no PS exposure on cells. To induce exposure of PS on the outer membrane of the cells, adult bovine aortic endothelial (ABAE) cells and 4T1 breast cancer cells were irradiated 24 hr earlier with a single dose of 6 Gy to induce exposure of PS on the outer membrane of the cells. For both cell types, specific binding of IO-PGN635F(ab ) 2 to PS was observed exclusively on the irradiated cells (Figs. 2(B) and (E)), but not on the non-irradiated cells (Figs. 2(A) and (F) ), evidenced by Prussian blue staining of irons (Figs. 2(B) and (E) ). The blue staining appeared to be surrounding the cells, indicating the IO-PGN635F(ab ) 2 was bound on the cell surface. The control conjugate IOAurexisF(ab ) 2 did not bind to the cells (Fig. 2(C) ) The specificity of IO-PGN635F(ab ) 2 was further confirmed by pre-incubating with non-labeled PGN635 to block the binding of IO-PGN635F(ab ) 2 (Fig. 2(D) ).
In Vitro MRI of PS-Targeting Specificity of IO-PGN635F(ab ) 2 Nanoprobes T 2 -weighted fast spin echo MRI was used to evaluate agarose phantoms containing 4T1 cells that were pre-incubated with various SPIO conjugates. In good agreement with the in vitro histological data, a marked reduction of SI was observed only in IO-PGN635F(ab ) 2 treated cells that were irradiated with 6 Gy (Fig. 3(A) ). A clear gradient of increased darkness was associated with increasing concentrations of the probes (Fig. 3(A) ). Minimal change of the signal observed for cells incubated with IO-AurexisF(ab ) 2 -or cells pre-incubated with nonlabeled antibody. Again confirming the specific binding of IO-PGN635F(ab ) 2 to exposed PS. Quantitative measurements of spin-spin relaxation time (T 2 showed significantly shortened T 2 values in the irradiated cells treated with IO-PGN635F(ab ) 2 , as compared to the control cells treated with PBS or the non-irradiated counterpart (Figs. 3(B) and (C); p < 0 05). A maximal reduction on T 2 was observed for the highest concentration of IO-PGN635F(ab ) 2 
(Figs. 3(B) and (C)).
Exposed PS on Blood Vessels of 4T1 Tumors In Vivo An average of 28 ± 8% of blood vessels in non-irradiated tumors had exposed PS on their endothelium, as judged by coincident staining of vessels by PGN635 and anti-CD31 (Fig. 4) . Twenty-four hours after a single dose of 12 Gy, PGN635 binding was significantly increased indicating increased levels of exposed PS in the tumors. PGN635 staining predominantly co-localized with tumor vessels (61 ± 8%; p < 0 001; Fig. 4 ).
In Vivo MRI Detection of IO-PGN635F(ab ) 2 in 4T1 Tumors
Longitudinal MRI was performed before and after i.v. injection of IO-PGN635F(ab ) 2 or IO-AurexisF(ab ) 2 .
As shown in Figure 5 , increased intratumoral hypointense regions, caused by specific binding of IO-PGN635F(ab ) 2 to exposed PS, were clearly visualized in both the nonirradiated and irradiated tumors as early as 2 hrs post IO-PGN635F(ab ) 2 , as compared to pre-injection baseline images. Inhomogeneous distribution of the nanoprobes appeared throughout the tumors. As expected, irradiation significantly enhanced PS exposure, resulting in more IO-PGN635F(ab ) 2 binding than that in the non-irradiated tumor. Follow-up MRI showed that the darkened regions in the irradiated tumor became more evident at 8 hr and persisted up to 48 hrs post injection. The time course of normalized tumor/muscle ratio (TMR) of T 2 -weighted signal intensity showed a minimal TMR value at 2 hr for both the non-irradiated (22 ± 7%) and irradiated (34 ± 9%) tumor, which gradually recovered to the baseline level in the nonirradiated tumor, but stayed at low level in the irradiated tumor ( Fig. 5(B) ). Histological analysis confirmed that blue stained IO-PGN635F(ab ) 2 co-localized with CD31-positive endothelial cells in non-irradiated tumor tissues ( Fig. 5(C) ). Consistent with imaging data, there were more IO-PGN635F(ab ) 2 nanoprobes binding to blood vessels of the irradiated tumors ( Fig. 5(D) ).
Spatial 'Hot-Spots' Analysis of Intratumoral Distribution of IO-PGN635F(ab ) 2 To provide better understanding of the spatial distribution of IO-PGN635F(ab ) 2 in tumor, 'hot-spots' maps of the hypointense regions were created. Post IO-PGN635F(ab ) 2 , an increased number of hot-spots, typically seen as punctuate, were located in both central and peripheral regions of non-irradiated tumors (Fig. 6(A) ), indicating baseline levels of PS exposure on tumor vascular endothelium. For the irradiated tumor, a dramatic increase in the number of hot-spots was observed after IO-PGN635F(ab ) 2 . In addition to the punctate pattern, most hot-spots in the irradiated tumor are clustering (Fig. 6(A) ). In vivo specific binding of IO-PGN635F(ab ) 2 was further confirmed by observing the lack of change in SI or hot-spots after injection of the control antibody conjugates, IO-AurexisF(ab ) 2 . Dynamic change in fractions of hot-spots is plotted in Figure 6 (C). For the group of tumors receiving IO-PGN635F(ab ) 2 (n = 6), mean fractions of hot-spots increased significantly in both the irradiated and non-irradiated tumors, with the maximal increase of 5.0 ± 1.1% and 2.7 ± 0.4%, respectively (p < 0 05; Fig. 6(C) ). Essentially no change was observed for the IO-AurexisF(ab ) 2 group (n = 4).
DISCUSSION
The present study demonstrates the feasibility of using PGN635F(ab ) 2 -conjugated, PEGylated IO nanoparticles for in vivo MR imaging of PS exposed on vasculature of breast tumors. In vivo MRI detected inhomogeneous signal loss in peripheral and central regions of the tumors due to IO-PGN635F(ab ) 2 binding. In contrast to the punctate distribution pattern in non-irradiated tumors, clustering hypointense regions were seen after a single dose of 12 Gy radiation, indicating that IO-PGN635F(ab ) 2 can be used to detect increases in PS exposure induced by radiotherapy. The heterogeneous distribution of the nanoprobes detected by MRI correlated well with histological studies showing that IO-PGN635F(ab ) 2 localized specifically to tumor vascular endothelial cells. The antigen-binding specificity of IO-PGN635F(ab ) 2 was verified by competition experiments with unconjugated PGN635 and by the lack of signal change with the non-binding control IO-AurexisF(ab ) 2 .
Much of the MRI data described in this report agree with our previous study using 800CW-PGN635F(ab ) 2 for optical imaging of gliomas growing in mice. 18 A clear tumor contrast in non-irradiated U87 gliomas was visualized as early as 4 hrs after injection of 800CW-PGN635F(ab ) 2 by near infrared optical imaging. Irradiation enhanced the tumor contrast in both subcutaneous and orthotopic U87 gliomas. However, the MRI data of the present study differed from the optical data in both signal distribution and magnitude change. Optical signals appeared to be homogeneously derived from the whole tumor, while only small fractions of tumor regions were detected as hypointense by MRI (2.7% for non-irradiated and 5% for irradiated tumors; Figs. 5 and 6). Moreover, optical imaging revealed an tumor/normal ratio of ∼ 3 for non-irradiated tumors and 4 for irradiated tumors, while 22% and 34% MRI signal intensity change was observed for the non-irradiated and irradiated tumor, respectively (Fig. 5(B) ). These variations provide a good example of how the two imaging modalities differ in terms of sensitivity and spatial resolution. Compared to optical and nuclear imaging methods, MRI is limited by its inherent low sensitivity. Low concentration of contrast agents, e.g., in the nanomolar range, is insufficiently detectable by MRI, but can emit enough photons for optical imaging to capture. Thus, MRI imaging of IO-PGN635F(ab ) 2 in this study may underestimate the tumor regions where PS is exposed on tumor vessels. However, the drawbacks of optical imaging such as light reflection, scattering and limited tissue penetration attribute to its low spatial resolution. We also noticed a difference in the intratumoral distribution between IO-PGN635F(ab ) 2 and 800CW-PGN635F(ab ) 2 in the irradiated tumors. In addition to tumor vascular localization, the optical 800CW-PGN635F(ab ) 2 (dye:antibody = 1:1) were also seen binding to tumor cells after irradiation induced PS exposure. IO-PGN635F(ab ) 2 , which are IO nanoparticles conjugated with multiple large antibody fragments (n = 18), were exclusively confined to tumor vessels ( Fig. 5(C) ). This suggests that specific homing of the IO-PGN635F(ab ) 2 to vasculature is responsible for the MRI signal change. Moreover, the data of the control antibody conjugates, IO-AurexisF(ab ) 2 suggested a minimal enhanced permeability and retention (EPR) effect of the IO conjugates which has also been described in previous reports by others. 8 21 Kiessling and colleagues have recently shown in their studies of v 3 -targeted MR imaging that RGD-conjugated SPIO (10 nm in diameter) are observed predominantly on v 3 -expressing tumor vasculature of several mouse tumor models. 8 However, Xie et al. found that RGD-conjugated ultrasmall SPIO (4.5 nm) dramatically increased cellular uptake by tumor cells. 22 Thus, increasing particle size, e.g., by encapsulating IO into micelles or liposomes, will probably enhance vascular localization if blood vessels are the desired targets. 7 Unlike the T 1 contrast agent, gadolinium-DTPA, SPIO is a T 2 contrast agent, which generates negative contrast on T 2 or T * 2 -weighted images. In comparison to paramagnetic T 1 contrast, SPIO has much higher molar relaxivity, thus, is widely used for molecular imaging applications by MRI. 23 24 Signal loss due to SPIO shortening of T 2 relaxation time is often difficult to discriminate from background tissue with varying contrast, as induced by B 0 inhomogeneity or susceptibility artifacts. Moreover, regional signal increase during the longitudinal study was often observed in some of the tumors of the current study, which may be caused by pathophysiological changes such as edema, hemorrhage or necrotic formation. Given the small population of tumor vascular endothelial cells in tumor tissues, a simple analysis by comparing an average T 2 signal loss or T 2 reduction may compromise the interpretation of signal change induced by targeted IO, proved to be less informative about spatial distribution of the vascular localized nanoprobes. Therefore, hot-spots analyses of the hypointense regions before and after injection of IO nanoprobes were applied to distinguish IO-induced signal voids from initial baseline level of dark signals, and gain spatial distribution information.
Successful cancer imaging requires imaging probes that recognize cancer-specific markers with great specificity and sensitivity. [25] [26] [27] Cell surface-exposed PS is an attractive target for molecular imaging. PS is strictly located in the inner leaflet of the plasma membrane bilayer in most normal cell types, including the vascular endothelium. Recent studies by Thorpe's lab have demonstrated that the oxidative stress within tumor microenvironment causes redistribution of phosphatidylserine (PS), the most abundant anionic phospholipid of the cell membrane, from the inner to the outer membrane leaflet of tumor endothelial cells. 10 11 Vascular endothelium in normal tissues, even in those highly angiogenic ovarian blood vessels during ovulation, lacks exposed PS. Examination of a large panels of tumor types of mouse and rat models revealed that PS exposure on tumor vasculature is an universal phenomenon despite the extent of exposure varies between tumors. 13 Thus, development of PS targeted nanoparticlebased imaging contrast has a great potential for imaging various tumor types. The PS exposed endothelial cells are viable and not subjected to apoptotic process. 28 29 These cells can resume growth and reestablish phospholipid asymmetry, which is distinct from the irreversible process occurring in cell death. 29 30 Besides tumor vasculature, loss of PS asymmetry commonly occurs during apoptosis and necrosis. 30 Much interest has been generated in developing molecular imaging probes to noninvasively monitor the response of tumors to various treatments from the induction of tumor apoptosis. 27 31 Annexin V is the PS binding ligand that is most widely used for this purpose. PGN635 and bavituximab, a chimeric monoclonal antibody that is currently evaluated in clinical trials, 32 have a more restricted specificity for PS than does annexin V, which recognizes PE in addition to PS and other anionic phospholipids.
CONCLUSIONS
In summary, we have developed a tumor vascular targeted imaging nanoprobe for MR imaging. By conjugating PGN635F(ab ) 2 , a novel monoclonal PS targeting antibody, with PEG-coated iron oxide nanoparticles, we detect heterogeneous intratumoral distribution of the nanoprobes by MRI, which coincides with tumor vascular endothelial cells. Irradiation increases PS exposure of tumor vasculature, which leads to significantly increased MRI contrast. The high specificity of PGN635-IO nanoprobes establishes PS as an alternative and unique vascular biomarker for molecular imaging of tumor vasculatures.
